Liminatus Pharma, Inc. (LIMN) Form 10-Q — May 15, 2026
Liminatus Pharma reported a net loss of $1.12 million for the first quarter of 2026, driven by increased general and administrative expenses and new research and development costs for its IBA101 candidate. The company ended the quarter with only $1.9 million in cash and an accumulated deficit of nearly $40 million, prompting management to disclose substantial doubt about its ability to continue as a going concern. The filing reveals significant governance and listing risks, including material weaknesses in internal controls over financial reporting due to inadequate segregation of duties and lack of formalized oversight.
Key figures
- Revenue
- 0
- Total Debt
- 1442500
- Cash Position
- 1907674
- Shares Outstanding
- 44877633
- Offering price
- 0.29
- Warrant liability
- 33422
- Related party debt
- 1442500
- Accumulated deficit
- -39995447
- Offering net proceeds
- 3440000
- Shares offered common
- 8270000
- Shares offered warrants
- 13813000
- Deferred underwriting fee payable
- 500000
- Shares offered prefunded warrants
- 5543000
Price after filing
Close on the filing date to close N calendar days later (from $0.18). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.